Tagged with Switzerland

Switzerland The Services Delivery Director for Life Sciences of NNIT Switzerland talks big data and highlights how this trend needs to be approached in order to create value for companies in the life science industry. You first joined NNIT in 2010; you then moved to the FMCG sector for a few…

Switzerland Daniel Schmutz, CEO of Switzerland’s leading insurance company, Helsana, sketches out the Swiss health insurance landscape, how his company maintains its market leader position, and working with both national and international partners to create better products for its customers and a more efficient insurance system. With 1.9 million policy takers…

Switzerland LEO Pharma’s Country Lead for Switzerland, Patrick Brunner, discusses the skincare specialist’s most important products, the Swiss affiliate’s significance to the global group, and the exciting new partnership with AstraZeneca. LEO Pharma Switzerland was established back in 1991 meaning that, last year, you celebrated 25 years of in-country operations. Could…

Switzerland The President of FASMED—the Swiss medical technology industry and trade association—elaborates on the plans to join forces with Medical Cluster, the other national medical technology organization, and highlights the current challenges facing the industry in Switzerland. Mr Gasche, you have a very interesting background, in the sense that you have…

Switzerland Ensuring a fair allocation of rights and returns from collaboratively developed technologies is a continual challenge for university Tech Transfer Offices – swiTT president Stefan Kohler discusses the current challenges and shares his perspective on the role of university developed IP in the Swiss life science ecosystem. What are some…

Switzerland Beat Berger (BB) and Dr Uwe Schmelzer (US) of Swiss API distributor DCS Pharma discuss growth segments in the global generics market, international hotspots, and the benefits of being based in Switzerland.   As an API distributor, what segments of the global generics market do you see the most growth…

Switzerland Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in pricing processes argues Gebro Pharma Switzerland CEO Marcel Plattner. We understand you serve as the head of the executive committee for market access and pricing within the…

Switzerland Ulf Claesson provides a fascinating and passionate account of how his firm is aiming to remove ‘guesswork’ and estimations for medical practices whilst highlighting interesting developments in the global clinical research industry. To begin with, we understand that you are a bit of a spin-out & start-up artist, and have…

Switzerland Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure medication, and the intricacies of market access in Switzerland. Could you please start by introducing Servier’s Swiss affiliate? We enjoy a longstanding presence and reputation in Switzerland. The local affiliate…

Switzerland The CEO of Max Zeller, a Swiss Phytopharmaceutical company, highlights the immense benefits his products have and furthermore discusses the company’s internationalization strategy. Mr Boonen, you joined Max Zeller in June 1999 and have spent almost all your professional career here. How have you seen the company evolve over time…

Switzerland Santen’s Head of EMEA explains why the company established their new regional headquarters in Geneva, Switzerland and highlights the three key strategic pillars on which he bases the growth strategy for the region.   The immense talent present here contributes to the strategic value of the EMEA region, which we…

Switzerland How would you present the strengths of the Lake Geneva region’s strengths to our international audience? The Lake Geneva region, which we often call the ‘health valley of Switzerland’, benefits from having two intersecting innovative clusters, one in MedTech and another in biotech. Looking at the course of life sciences…